AOA Dx

Are you going to the Annual Advancing Precision Medicine conference? Don't miss Oriana Papin-Zoghbi's panel discussion with Sarah Huah!

The belief that ovarian cancer is a 'silent killer' is outdated and has been dispelled. This editorial by Barbara A. Goff, MD, highlights that more than 70% of women with early-stage, high-grade serous ovarian cancer experience symptoms before diagnosis. At AOA Dx, we’re committed to advancing early detection and empowering women and healthcare professionals to recognize these signs sooner. Early diagnosis saves lives.

We’re so proud that our CEO, Oriana Papin-Zoghbi, has been selected as a fellow and is participating in the Health & Longevity Summit this week. The summit brings together a distinguished faculty of scientists leading medical advancements that are making a real impact today. DOC's inaugural agenda highlights actionable insights into neuroscience, longevity, artificial intelligence, cancer, the microbiome, cardiovascular health, and more. DOC participants have the opportunity to engage in credible scientific tests that illuminate biology, sleep, and brain health and to discuss their results with the DOC faculty. 👏

What a week at HLTH USA. It was so inspiring to see women's health take center stage in so many impactful conversations at #HLTH2024! Our investor, Alice Zheng, Partner at Foreground Capital, took the stage to join the panel, 'The Under-researched, Under-diagnosed, and Overlooked Truth About Women's Health" alongside Lucy Perez, Senior Partner at McKinsey & Company, Frederique Dame, GP at GV (Google Ventures), Marlena Fejzo, CSO of Harmonia Healthcare, and Sophia Yen, MD, MPH, Co-Founder and CMO of Pandia Health. It was great to connect with industry leaders, investors, fellow innovators, partners and more this week. Let's keep shaping the future of women's health together! CC: Oriana Papin-Zoghbi, Ariel Kramer, Martin Sandgren, Klover Communications, Marissa Fayer, DeepLook Medical, Pita Navarro, Evvy, Heather Bowerman, DotLab

We are so proud to be named a Finalist for the Rising Star of the Year by the Colorado BioScience Association! Colorado has been an incredible place to grow our team and we continue to thrive with the abundance of talent, support, and community here. "Founded in 2020, AOA Dx is at the forefront of developing a novel frontier in early-stage cancer detection for women. After raising an oversubscribed $17 million seed round led by Good Growth Capital with participation from Foreground Capital, Y Combinator, Astia, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors. AOA Dx relocated to Colorado in 2024 and has continued to gain recognition for its groundbreaking work in research publications and national news outlets, including BMJ Oncology, American Society of Clinical Oncology, American Association for Cancer Research, The New York Times, and the Wall Street Journal.  " Cheers to all the Finalists!!!👏

Early detection is crucial in ovarian cancer because 80% of patients are diagnosed at advanced stages, when the disease is harder to treat and survival rates are significantly lower. Identifying ovarian cancer earlier can drastically improve outcomes, offering a better chance for effective treatment and longer survival.

Have you met our Senior Clinical Trials Specialist Michael Matthews? Here's a glimpse into his work day with AOA Dx! "I am proud to contribute to AOA's mission of transforming women's health. As a member of the clinical operations team, I work closely with the investigators and research staff who enroll subjects to our clinical study. The generosity of these patients participating in our study enables our incredible team of scientists to create a world where more women are living longer, healthier lives through the power of early ovarian cancer detection!" - Michael Matthews

We are proud to be featured in the Colorado BioScience Association Magazine! Thank you for highlighting the work we are doing in women's health. We are so happy we made Denver our HQ and truly impressed by the talent and community here. Our co-founder Anna Milik Jeter even helped open our Denver HQ (3 DAYS) before giving birth! While many women hear that their careers will stall if they choose to have children, we’re proving the opposite for women that want to do both. Anna welcomed a beautiful addition to her family earlier this year! Read the full story here: https://lnkd.in/d9tcMsQw Ft: Oriana Papin-Zoghbi Alexander Fisher Abigail McElhinny

Check out our CEO + Co-Founder Oriana Papin-Zoghbi featured in Femtech World! "What is your greatest achievement since establishing AOA? Building our team has been our greatest achievement and the most significant learning curve. While we’ve had success in raising capital, publishing papers, de-risking our technology, making progress on our milestones, etc, none of this would have been possible without our team. My co-founders, Alex, Anna, and I have worked diligently to assemble a phenomenal group of individuals who are truly passionate and committed to AOA." Read the full interview here: Thank you Sorina Mihaila for the opportunity!

Huge congratulations to Professor Ahmed Ashour Ahmed, Director of the Ovarian Cancer Cell Laboratory at the University of Oxford and leader of the OvarianVax project. "The project to develop the vaccine, funded by Cancer Research UK (CRUK), will first focus on women who have mutations in the BRCA1 or BRCA2 genes. Most commonly known to significantly increase the risk of developing breast cancer, carriers of BRCA gene mutations also have an increased risk of developing ovarian cancer. Women in the general population have around a 2% lifetime risk of ovarian cancer, but in people carrying BRCA gene mutations, lifetime risk is up to 45%." Great read by Victoria Forster: